Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation

Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X

Xu, 2000, Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand, J. Bone Miner. Res., 15, 2178, 10.1359/jbmr.2000.15.11.2178

Boyce, 1999, Required and nonessential functions of nuclear factor-kappa B in bone cells, Bone, 25, 137, 10.1016/S8756-3282(99)00105-2

Xu, 2009, NF-kappaB modulators in osteolytic bone diseases, Cytokine Growth Factor Rev., 20, 7, 10.1016/j.cytogfr.2008.11.007

Guengerich, 1990, Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene, Chem. Res. Toxicol., 3, 363, 10.1021/tx00016a015

Jagetia, 2002, The grapefruit flavanone naringin protects against the radiation-induced genomic instability in the mice bone marrow: a micronucleus study, Mutat. Res., 519, 37, 10.1016/S1383-5718(02)00111-0

Jagetia, 2003, Naringin, a citrus flavonone, protects against radiation-induced chromosome damage in mouse bone marrow, Mutagenesis, 18, 337, 10.1093/mutage/geg001

Attia, 2008, Abatement by naringin of lomefloxacin-induced genomic instability in mice, Mutagenesis, 23, 515, 10.1093/mutage/gen045

Wei, 2007, Anti-osteoporosis activity of naringin in the retinoic acid-induced osteoporosis model, Am. J. Chin. Med., 35, 663, 10.1142/S0192415X07005156

Mandadi, 2009, Citrus bioactive compounds improve bone quality and plasma antioxidant activity in orchidectomized rats, Phytomedicine, 16, 513, 10.1016/j.phymed.2008.09.001

Pavlos, 2005, Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption, Mol. Cell Biol., 25, 5253, 10.1128/MCB.25.12.5253-5269.2005

Ang, 2011, Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-kappaB and ERK, J. Cell Biochem., 112, 89, 10.1002/jcb.22800

Yip, 2006, P62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget’s disease of bone, Am. J. Pathol., 169, 503, 10.2353/ajpath.2006.050960

Ang, 2009, Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity, J. Cell Physiol., 221, 642, 10.1002/jcp.21898

Ang, 2007, Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL), J. Cell Physiol., 212, 787, 10.1002/jcp.21076

Wang, 2003, 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation, J. Bone Miner. Res., 18, 2159, 10.1359/jbmr.2003.18.12.2159

Hsu, 1999, Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, Proc. Natl. Acad. Sci. USA, 96, 3540, 10.1073/pnas.96.7.3540

Yamamoto, 2002, Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand, J. Bone Miner. Res., 17, 612, 10.1359/jbmr.2002.17.4.612

Zhang, 2001, Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways, J. Biol. Chem., 276, 563, 10.1074/jbc.M008198200

Franzoso, 1997, Requirement for NF-kappaB in osteoclast and B-cell development, Genes Dev., 11, 3482, 10.1101/gad.11.24.3482

Iotsova, 1997, Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2, Nat. Med., 3, 1285, 10.1038/nm1197-1285

Hotokezaka, 2002, U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells, J. Biol. Chem., 277, 47366, 10.1074/jbc.M208284200

Matsumoto, 2000, Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor, FEBS Lett., 486, 23, 10.1016/S0014-5793(00)02231-6

Matsumoto, 2000, Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL), J. Biol. Chem., 275, 31155, 10.1074/jbc.M001229200

Tsai, 1999, Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol, Br. J. Pharmacol., 126, 673, 10.1038/sj.bjp.0702357

Kawaguchi, 1999, Suppression of lipopolysaccharide-induced tumor necrosis factor-release and liver injury in mice by naringin, Eur. J. Pharmacol., 368, 245, 10.1016/S0014-2999(98)00867-X

Kawaguchi, 2004, Suppression of infection-induced endotoxin shock in mice by a citrus flavanone naringin, Planta Med., 70, 17, 10.1055/s-2004-815449

Kanno, 2006, Inhibitory effect of naringin on lipopolysaccharide (LPS)-induced endotoxin shock in mice and nitric oxide production in RAW 264.7 macrophages, Life Sci., 78, 673, 10.1016/j.lfs.2005.04.051

Kwan Tat, 2004, IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology, Cytokine Growth Factor Rev., 15, 49, 10.1016/j.cytogfr.2003.10.005

Lin, 2007, Alteration of bone cell function by RANKL and OPG in different in vitro models, Eur. J. Clin. Invest., 37, 407, 10.1111/j.1365-2362.2007.01800.x

Nam, 2006, Naturally occurring NF-kappaB inhibitors, Mini Rev. Med. Chem., 6, 945, 10.2174/138955706777934937